PRESS RELEASE · PRESS RELEASE · PRESS RELEASE
NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY
FOR IFNalpha KINOID IN TYPE 1 DIABETES
Company intends to continue preclinical development in this indication in 2018
Paris and Boston, December 12th 2017, 07:00 am CET - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced positive initial results from its ongoing proof-of-concept (PoC) preclinical studies with IFNalpha Kinoid for the treatment of Type 1 Diabetes (T1D).
The ongoing PoC preclinical studies in Type 1 Diabetes in non-obese diabetic (NOD) mice[1], conducted in collaboration with Dr. Agnès Lehuen and Pr. Christian Boitard, from the department of Immunology of Diabetes at the Hospital Cochin in Paris, have confirmed:
-
A strong production of neutralizing antibodies to IFNalpha following IFNalpha Kinoid administration
-
A twice higher preservation of Langerhans islets[2] is observed in mice treated with IFNalpha Kinoid compared to the control groups.
-
A notable delay in the onset of Type 1 Diabetes in relation to the persistence of anti-IFNalpha neutralizing antibodies
"In this initial preclinical study for the treatment of type 1 diabetes, we observed a delay in the triggering of the pathology, which was maintained for several weeks." said Miguel Sieler, Chief Executive Officer of Neovacs. "Additionally, the protection of Langerhans islets suggests that the IFNalpha Kinoid vaccine could have a preventive action. Based on these promising results, we look forward to finalizing our trials, with the goal of initiating a clinical development program in type 1 diabetes in the near future." Neovacs expects to complete this study in 2018 in order to fully evaluate the therapeutic potential of IFNalpha Kinoid in T1D. These final results will guide the protocol of Neovacs` first clinical study in this indication.
IFNalpha Kinoid is an anti-interferon-alpha vaccine that is currently in clinical development in several indications. Neovacs previously demonstrated in its Phase I/IIa[3] clinical study of IFNalpha Kinoid in Lupus that the persistence of neutralizing antibodies for several years can be achieved with the Company`s vaccine candidate and is also capable of neutralizing the Interferon signature. A Phase IIb study is currently ongoing with IFNalpha Kinoid for the treatment of Lupus.
About Type 1 Diabetes
Type 1 Diabetes is an autoimmune disease which is foreseen to affect 25 million people in the world by the year 2020 with growing incidence worldwide (+3%pa). Source WHO. This disease may cause severe and even life threatening complications and has no curative treatment. Patients have to monitor their glycaemia throughout the day and are treated with multiple insulin injections over their lifetime.